My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

AbbVie (NY:ABBV)

229.48 +4.67 (+2.08%)

Official Closing Price Updated: 7:00 PM EST, Feb 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

94 95 Next >

Nuclear Threats, Trump Fires Labor Statistics Chief, Fed Governor Resigns And More: This Week In Politics ↗

August 03, 2025

Via Benzinga

Topics Economy Government

3 Unstoppable Stocks to Buy in August ↗

August 02, 2025

Here are hot stocks to buy in a hot month.

Via The Motley Fool

Topics Intellectual Property

3 Dividend Champion Stocks I'm Watching in 2025 ↗

August 02, 2025

Other investors might want to watch these high-yield dividend stocks, too.

Via The Motley Fool

Topics Earnings Government World Trade

Expert Outlook: AbbVie Through The Eyes Of 4 Analysts ↗

August 01, 2025

Via Benzinga

Why AbbVie Stock Flew Higher on Friday ↗

August 01, 2025

A solid quarterly earnings report reverberated though the pundit community that day.

Via The Motley Fool

Meta, Microsoft Power Wall Street To New Records Despite Inflation Jump: What's Moving Markets Thursday? ↗

July 31, 2025

A post-earnings surge in Meta Platforms Inc. (NASDAQ:META) and Microsoft Corp.

Via Benzinga

Topics Economy

Earnings Scheduled For July 31, 2025 ↗

July 31, 2025

Via Benzinga

A Peek at AbbVie's Future Earnings ↗

July 30, 2025

Via Benzinga

Discover which S&P500 stocks are making waves on Friday. ↗

August 01, 2025

Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.

Via Chartmill

AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion ↗

August 01, 2025

AbbVie raised full-year guidance after Q2 sales beat expectations, with analysts lifting price targets despite an earnings miss.

Via Benzinga

Topics Earnings

Deal Dispatch: MEG Bidding War Heats Up, L Catterton Takes Bite Out Of Kisshokichi, Sunnova's Still Shining ↗

August 01, 2025

Big-name bidders, strategic reviews, and PE exits define an active, high-stakes M&A market so far this summer.

Via Benzinga

5 Dividend Stocks With Solid Returns And More Growth Ahead ↗

August 01, 2025

Via Benzinga

Why AbbVie (ABBV) Stock Is Up Today

August 01, 2025

Shares of pharmaceutical company AbbVie (NYSE:ABBV) jumped 3.7% in the afternoon session after the company posted strong second-quarter earnings that beat expectations and raised its full-year...

Via StockStory

3 Dividend Healthcare Stocks to Buy Hand Over Fist Before They Double ↗

August 01, 2025

These pharmaceutical giants are well worth a second look.

Via The Motley Fool

Trump Issues 60 Day Ultimatum To US Pharma Giants To Slash Drug Prices: 'If You Refuse To Step Up We Will...' ↗

August 01, 2025

President Donald Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences.

Via Benzinga

Topics Government

Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch ↗

July 31, 2025

Via Stocktwits

Topics Government

Why AbbVie Stock Slumped Today ↗

July 31, 2025

An encouraging quarterly earnings report was dampened by a new demand from President Trump.

Via The Motley Fool

Topics Government

AbbVie Stock Eyes Breakout as Pipeline and Profits Grow ↗

July 31, 2025

AbbVie stock pops after strong Q2 earnings and raised guidance, as Skyrizi and Rinvoq offset Humira's decline and support a bullish outlook

Via MarketBeat

AbbVie Lifts Outlook, Eyes Parkinson's Assets As Next Growth Frontier ↗

July 31, 2025

AbbVie posted $15.42 billion in Q2 revenue, topping estimates, with strong immunology and neuroscience growth, while full-year earnings guidance was raised.

Via Benzinga

AbbVie CEO Sees ‘Substantial Momentum’ For Remaining Year After Q2 Earnings Beat: Retail’s No Longer Pessimistic ↗

July 31, 2025

For the full year, the company raised its adjusted and diluted earnings per share guidance to $11.88 to $12.08, up from its previous guidance of $11.67 to $11.87.

Via Stocktwits

Topics Intellectual Property

AbbVie Inc (NYSE:ABBV) Beats Q2 2025 Earnings and Revenue Estimates, Raises Full-Year Guidance ↗

July 31, 2025

AbbVie beats Q2 2025 revenue and EPS estimates, raises full-year outlook. Stock surges 4.59% pre-market on strong portfolio performance and pipeline progress.

Via Chartmill

AbbVie’s (NYSE:ABBV) Q2: Beats On Revenue

July 31, 2025

Pharmaceutical company AbbVie (NYSE:ABBV) announced better-than-expected revenue in Q2 CY2025, with sales up 6.6% year on year to $15.42 billion. Its non-GAAP profit of $2.97 per share was 2.1% above...

Via StockStory

AbbVie Retail Traders Remain Wary Amid Report Of $1B Gilgamesh Deal To Boost Mental Health Pipeline ↗

July 30, 2025

The potential acquisition follows a 2023 licensing partnership between the two companies and comes after Gilgamesh reported promising trial results for its depression drug, GM-2505.

Via Stocktwits

Topics Intellectual Property

10 Health Care Stocks Whale Activity In Today's Session ↗

July 30, 2025

Via Benzinga

Got $500? 3 Blue Chip Dividend Stocks to Buy and Hold Forever ↗

July 30, 2025

Being a great investor doesn't have to be complicated or expensive.

Via The Motley Fool

Topics Intellectual Property

AbbVie (ABBV) Reports Q2: Everything You Need To Know Ahead Of Earnings

July 29, 2025

Pharmaceutical company AbbVie (NYSE:ABBV) will be reporting earnings this Thursday before market open. Here’s what investors should know.

Via StockStory

Topics Artificial Intelligence

Eli Lilly’s Cancer Drug Demonstrates Better Effectiveness Than AbbVie’s In Late Stage Trial: Retail Believes In Holding The Stock ↗

July 29, 2025

Jaypirca had an overall response rate better than AbbVie’s Imbruvica in the study, meaning a higher percentage of patients treated with Jaypirca experienced their cancer shrink or disappear after...

Via Stocktwits

Why Is ATAI Life Sciences Stock Trading Lower On Monday? ↗

July 28, 2025

Recognify's CIAS trial for inidascamine missed its main endpoint but showed positive signals in cognitive domains and had a favorable safety profile.

Via Benzinga

2 Top Dividend Stocks to Buy Right Now and Hold Forever ↗

July 28, 2025

Long-term shareholders have already seen significant gains from these stocks, and there's likely much more to come for patient investors.

Via The Motley Fool

Topics Intellectual Property

3 Value Stocks with Questionable Fundamentals

July 28, 2025

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...

Via StockStory

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

94 95 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.